12 completed, 5 terminated, 3 withdrawn, 2 active not recruiting. 6 Not applicable, 6 Phase 1, 5 Phase 2, 5 Phase 4, 2 Early Phase 1.
Follow Narcan: new trials by email Literature Review of Narcan trials Research Report on Narcan
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Naloxone for Opioid Associated Out of Hospital Cardiac Arrest Naloxone 2 MG, Saline 2ml - Heart Arrest, Out-Of-Hospital, Opioid Overdose | Phase 2 | Not yet recruiting | University of California, San Francisco | 98 | 2027-03-01 | 2026-09-11 |
| A Universal Primary Care Based Intervention to Reduce Youth Overdose Risk Brief youth overdose prevention education, Information about Naloxone, Usual standard of care - Overdose | Not applicable | Active not recruiting | Boston Medical Center | 22 | 2025-08-25 | 2026-08-07 |
| Clinical Outcomes From Nalmefene Nalmefene Hydrochloride Injection, Naloxone Hydrochloride Injection - Opioid Overdose | Phase 4 | Withdrawn | Purdue Pharma LP | 2023-06-01 | 2023-07-12 | |
| Pharmacodynamic Evaluation of Intramuscular Nalmefene Autoinjector 1.5 mg Compared to Intranasal Narcan 4 mg Nalmefene HCl injection, Naloxone HCl intranasal - Opioid Overdose | Phase 1 | Completed | Purdue Pharma LP | 24 | 2022-10-03 | 2025-07-03 |
| Stress and Opioid Misuse Risk: The Role of Endogenous Opioid and Endocannabinoid Mechanisms Placebo, Oxycodone, Naloxone - Opioid Use Disorder, Back Pain | Phase 4 | Completed | Vanderbilt University Medical Center | 101 | 2022-03-02 | 2026-09-04 |
| Increasing Naloxone Access for Persons Who Use Opioids Opioid Overdose Education with Naloxone Distribution, Opioid Overdose Education - Naloxone | Phase 4 | Completed | University of Alabama at Birmingham | 111 | 2021-07-11 | 2023-10-30 |
| A Single-Dose, Bioequivalence Study of FMXIN001 4 mg Microspheres Powder Nasus Pharma FMXIN001, Nasal Naloxone liquid spray - Opioid Overdose | Phase 1 | Completed | Nasus Pharma | 46 | 2021-01-31 | 2022-05-02 |
| Efficacy of Spinal Manipulation Therapy or Mindfulness-based Reduction Therapy on Patients With Chronic Low Back Pain Spinal Manipulation Therapy (SMT), Naloxone, Placebo - Chronic Low-back Pain | Early Phase 1 | Active not recruiting | Rush University Medical Center | 140 | 2020-08-15 | 2025-07-10 |
| The Effect of Chronic Pain on Delay Discounting in Methadone Patients Naloxone Hydrochloride, Placebo - Opioid-use Disorder, Chronic Pain Syndrome | Phase 1 | Terminated | University of California, San Francisco | 10 | 2020-01-08 | 2025-03-26 |
| Measures to Improve Outcomes After an Opioid Overdose Buprenorphine/Naloxone - Opioid Overdose | Withdrawn | Nassima Ait-Daoud Tiouririne | 2019-08-01 | 2026-06-26 | ||
| Rapid Reversal of CNS-Depressant Drug Effect Prior to Brain Death Determination Flumazenil, Naloxone - Brain Death, Anoxic Brain Injury | Early Phase 1 | Withdrawn | Prisma Health-Midlands | 2019-01-01 | 2024-10-31 | |
| Comparison of Naloxone Pharmacokinetics Naloxone, Mucosal atomization device and syringe, Narcan - Opioid-use Disorder | Phase 1 | Completed | National Institute on Drug Abuse (NIDA) | 30 | 2018-01-03 | 2018-03-09 |
| Biology and Experience of Eating in Women With Obesity Naloxone, Placebo - Obesity | Phase 2 | Completed | University of California, San Francisco | 41 | 2017-05-20 | 2021-11-03 |
| A Tailored, Peer-delivered Intervention to Reduce Recurring Opioid Overdoses Peer Intervention, naloxone nasal spray kit, Personally-tailored opioid overdose prevention education (information packet) - Drug Overdose, Opioid-Related Disorders | Not applicable | Completed | University of Cincinnati | 80 | 2017-02-07 | 2020-06-24 |
| Intra-nasal Naloxone for Treatment of Impaired Awareness of Hypoglycemia intra-nasal naloxone, Intra-nasal saline - Hypoglycemia Unawareness, Type 1 Diabetes | Phase 1 / Phase 2 | Terminated | University of Minnesota | 11 | 2016-06-01 | 2023-03-27 |
| Evaluation of Intranasal Naltrexone and Naloxone Naltrexone, Naloxone, Naltrexol - Opioid-use Disorder | Phase 1 | Completed | National Institute on Drug Abuse (NIDA) | 12 | 2015-10-05 | 2020-09-14 |
| Naloxone for Optimizing Hypoxemia Of Lung Donors Naloxone, Normal saline - Brain Death, Organ Donors | Phase 2 / Phase 3 | Completed | Washington University School of Medicine | 199 | 2015-09-01 | 2020-07-31 |
| Reduced Opioid Analgesic Requirements Via Improved Endogenous Opioid Function 6 week aerobic exercise intervention, Placebo, Morphine - Chronic Pain | Not applicable | Completed | Vanderbilt University Medical Center | 117 | 2015-08-01 | 2020-09-23 |
| Nasal Naloxone for Narcotic Overdose Intranasal (IN) naloxone, Intravenous (IV) naloxone, Intramuscular (IM) naloxone - Drug Overdose | Phase 4 | Unknown | Judith Feinberg | 236 | 2013-09-01 | 2013-07-31 |
| Comparison of Two Naloxone Infusion Rates on the Postoperative Recovery of Patients Undergoing Spine Fusion Surgery Naloxone - Pain, Postoperative, Postoperative Nausea and Vomiting | Not applicable | Completed | Children's Mercy Hospital Kansas City | 84 | 2011-11-01 | 2020-09-10 |
Showing 20 of 24. Sign in to see all of them.
Opiate Overdose (6) · Opioid-Related Disorders (5) · Drug Overdose (3) · Brain Death (2) · Hypoglycemia (2) · Agnosia (1) · Back Pain (1) · Bulimia (1) · Chronic Pain (1) · Constipation (1) · Death (1) · Diabetes Mellitus (1) · Diabetes Mellitus, Type 1 (1) · Heart Arrest (1) · Hypoxia-Ischemia, Brain (1)
University of California, San Francisco (4) · National Institute on Drug Abuse (NIDA) (2) · Purdue Pharma LP (2) · Vanderbilt University Medical Center (2) · Albert Einstein College of Medicine (1) · Boston Medical Center (1) · CAMC Health System (1) · Children's Mercy Hospital Kansas City (1) · Judith Feinberg (1) · Mahidol University (1) · Nassima Ait-Daoud Tiouririne (1) · Nasus Pharma (1) · Prisma Health-Midlands (1) · Rush University Medical Center (1) · University of Alabama at Birmingham (1)
United States (20) · Canada (1) · Thailand (1)
Stephen Bruehl, PhD (3) · Amir Moheet, MD (1) · Amy Yule, MD (1) · Ashley E Mason, PhD (1) · Audis Bethea, PharmD, BCPS (1) · Benjamin J. Pieters, DO (1) · D. Andrew Tompkins, MD (1) · Debra Kelsh, MD (1) · Janice Faulknor, MD, CCFP (1) · John Burns, PhD (1) · Jon D Levine, MD, PhD (1) · Judith Feinberg, MD (1) · Meredith Hawkins, M.D., M.S. (1) · Michelle Sisson, MA (1) · Nassima Ait-Daoud Tiouririne, M.D. (1)
PMID 22522612, PMID 28860128, PMID 30399122, PMID 30640659, PMID 34236298, PMID 35386013, PMID 37091508, PMID 37336007, PMID 39514898
R01DA037891 (1), R01DA050334 (1), R01DE018526 (1), R01DK079974 (1), R21DA047520 (1), R34DA040862 (1), R61DA062217 (1)